Patient Perspective: Cardiac Amyloidosis

Scripps Health

M. Nichols

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Cardiac Amyloidosis: An Overlooked but Treatable Cause of HFpEF

Inova Heart and Vascular Institute - Advanced Heart Failure Symposium

SOHO 2022: Amyloidosis - Update and How To Use Novel Agents

SOHO 2022 Tenth Annual Meeting

S. Lentzsch

Amyloidosis Types and Pathophysiology

Houston Methodist

B. Trachtenberg

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

Emerging Therapies in Cardiac Amyloidosis

NYU Langone

M. Hanna

New Diagnostic and Treatment Strategies in Cardiac Amyloidosis

Canadian Collaborative Research Network

M. Davis

Assessment of Aortic Regurgitation in the Current Era

Houston Methodist DeBakey Heart and Vascular Center

W. Zoghbi

Hypertrophic Cardiomyopathy: MRI to Mavacamten

Scripps Health

J. Gonzalez

Therapies for Pulmonary Venous Hypertension: Updates on the Treatmen…

Scripps Health

R. Mohan

Cardiac Amyloidosis: Evaluation and New Therapies

Cleveland Clinic Heart, Vascular and Thoracic Institute

M. Hanna

MI With No Obstructive Disease: Is That a Thing

FACET

H. Hashim

Overview of Cardiac Amyloidosis

Yale Cancer Center

E. Miller

Evaluation of Left Ventricular Diastolic Function

Houston Methodist DeBakey Heart and Vascular Center

S. Nagueh

Non-Invasive Testing for the Diagnosis of PAD

NY Endovascular Summit

D. Kadian-Dodov

Interpreting a PYP Study for TTR Cardiac Amyloid

American Society of Nuclear Cardiology

P. Soman, M. Harinstein, S. Divakaran

Lessons from the 2023 ACC Expert Consensus Decision Pathway on Compr…

Michelle Kittleson

Imaging in Cardiomyopathy

Scripps Health

A. Srivastava

Perioperative Risk Assessment & Management: When Do I Need Cardiac T…

Houston Methodist DeBakey Heart and Vascular Center

N. Faza